Role of positron emission tomography in urological oncology

BJU International

Volumn 106, Issue 11, 2010, Pages 1593-1594

  Lawrentschuk, Nathan ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADVANCED CANCER; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; HIGH RISK PATIENT; HUMAN; NOTE; PENIS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TESTIS CANCER; URINARY TRACT CANCER;

HUMANS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; UROGENITAL NEOPLASMS;

EID: 78649258516     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09955.x     Document Type: Note

References (16)

1. Makarov DV, Loeb S, Getzenberg RH, Partin AW,. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 139 - 51
2. National Cancer Institute. Medical Dictionary. Available at:. Accessed May 2010
3. Rioja J, Rodríguez-Fraile M, Lima-Favaretto R, et al. Role of positron emission tomography in urological oncology. BJU Int 2010; 106: 1578 - 94
4. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA,. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7: 109 - 15
5. Zuckier LS, DeNardo GL,. Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997; 27: 10 - 29
6. Van Der Veldt AA, Meijerink MR, Van Den Eertwegh AJ, Haanen JB, Boven E,. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102: 803 - 9
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205 - 16
8. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST. Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl. 1): 122S - 50S
9. 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008; 102: 446 - 51
10. Poulsen MH, Bouchelouche K, Gerke O, et al. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010 [Epub ahead of print]. DOI:10.1111/j.1464-410X.2009.09191.x
11. Lawrentschuk N, Poon AM, Scott AM,. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med 2006; 31: 788 - 9
12. Nagengast WB, De Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313 - 9
13. Di Napoli A, Signoretti S., Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 2009; 115 (Suppl.): 2290 - 7
14. Eichelberg C, Junker K, Ljungberg B, Moch H,. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009; 55: 851 - 63
15. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825 - 30
16. Dilhuydy MS, Durieux A, Pariente A, et al. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation. Oncology 2006; 70: 339 - 44